Suggests reducing bone turnover below the midpoint of the reference range for the chosen monitoring bone turnover marker to maximize the duration of remission. Triggered when aiming to sustain long-term remission after treatment and the marker exceeds the midpoint.
Installs into .claude/skills of the current project.
Are you the author of Endo Paget Remission Target Turnover?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-paget-remission-target-turnover)
---
name: endo-paget-remission-target-turnover
description: Suggests reducing bone turnover below the midpoint of the reference range for the chosen monitoring bone turnover marker to maximize the duration of remission. Triggered when aiming to sustain long-term remission after treatment and the marker exceeds the midpoint.
---
# Target bone turnover below midpoint to maximize remission duration
## STEP 1 — Gather Information
Collect a bone turnover marker (serum total ALP, P1NP, BSAP, CTx, or NTx) and its laboratory reference range; calculate the midpoint of the reference range.
## STEP 2 — Rule In / Rule Out
If the post‑treatment marker value is above the midpoint, rule in the need for further suppression; if at or below the midpoint, rule out (target achieved).
## STEP 3 — Classify or Stratify
Stratify the degree of excess above midpoint: mild (1‑25% above), moderate (26‑50% above), marked (>50% above) to guide intervention intensity.
## STEP 4 — Decide
For mild excess, optimize current regimen and repeat marker in 3‑6 months; for moderate or marked excess, consider a repeat potent bisphosphonate (e.g., second zoledronate infusion) or switch to a more potent agent, then re‑evaluate the marker.
## Clinical Guardrails / Mimics / Pitfalls
Do not rely on symptoms alone; avoid over‑suppression that may cause adynamic bone; ensure adequate renal function before potent bisphosphonate; use least significant change to distinguish true change from assay variability; confirm marker specificity (e.g., bone‑specific ALP if liver disease); do not mistake transient fluctuations for true biological change.
## Concrete Clinical Example
A 68‑year‑old with polyostotic Paget’s disease received a single 5 mg IV zoledronate. Six months later serum ALP was 78 U/L (reference 30‑120 U/L, midpoint 75 U/L). Because the value was just above the midpoint, a second zoledronate infusion was given. At the following 6‑month visit ALP had fallen to 42 U/L (below midpoint), and the patient remained in biochemical remission at 5‑year follow‑up.
**Source:** Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2910
